1 / 11

Relative HEXIM1 levels

Supplement Fig. 1. HEXIM1 mRNA Modulation by JQ1 and volasertib ( qRT -PCR ). Relative HEXIM1 levels. 4h. 48h. 24h. JQ1. JQ1. JQ1. control. control. control. volasertib 20 mg/kg. volasertib 40 mg/kg. volasertib 20 mg/kg. volasertib 40 mg/kg. volasertib 20 mg/kg.

cozart
Télécharger la présentation

Relative HEXIM1 levels

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Supplement Fig. 1 HEXIM1 mRNA Modulation by JQ1 andvolasertib (qRT-PCR) Relative HEXIM1 levels 4h 48h 24h JQ1 JQ1 JQ1 control control control volasertib 20 mg/kg volasertib 40 mg/kg volasertib 20 mg/kg volasertib 40 mg/kg volasertib 20 mg/kg volasertib 40 mg/kg Increase of HEXIM-1 mRNA only in JQ1 treated samples (at 4h after application). JQ1: 150 mg/kg qd

  2. Supplement Fig. 2.1 MV-4-11B: 24h treatmentwith volasertib and/or BI 894999 FACS cellcycleanalysis Fig. 1: Cell Cycle Analysis of logarithmically growing MV-4-11B cells, incubated with 1x and 3x EC50 concentrations of volasertib and 0.3x, 1x and 3x EC50concentrations of BET inhibitor BI 894999 orcombination of both. Treatment for 24, 48 and72h followedby PI stainingandanalysis in FACScalibur. Percentagesof cells in therespectivecellcyclephasesareplotted.

  3. Supplement Fig. 2.2 MV-4-11B: 48h treatmentwith volasertib and/or BI 894999 FACS cellcycleanalysis

  4. Supplement Fig. 2.3 MV-4-11B: 72h treatmentwith volasertib and/or BI 894999 FACS cellcycleanalysis

  5. Supplement Fig. 3 Determination of Apoptosis by Caspase 3/7 staining Incucyteanalysis. MV-4-11B cellswere treated andanalyzedover time withtheIncuCyte™Caspase-3/7 Apoptosis Assay Reagent (Essenbioscience Cat No 4440) BI 894999 + volasertib: Increase in Caspase 3/7 staining in thecombinationsetting( ) Method: Incucyteassay MV-4-11B cells were plated (1×104/well) in 96-well plates (BD BioCoat poly-d-lysine–coated black/clear bottom plate). The next day, compounds were added at the concentrations indicated. For apoptosis detection, Cell Player Kinetic caspase-3/7 Reagent (Essen BioScience, Ann Arbor, MI), diluted in medium to a final concentration of 1.25 µM was added at the same time. Cell confluence and green fluorescence as a measure of caspase-3/7 activation were monitored for 36 hours with images taken every 3 hours.

  6. Supplement Fig. 4 Method: Immunofluorescence staining Cytospins were fixed, permeabilized and stained as described earlier (Rudolph 2009). As first antibody anti-tubulin (Sigma T6199) was diluted 1:1000 and anti-phospho-histone H3 antibody (Cell Signaling #9701) 1:200, in PBS 2% bovine serum albumin, followed by fluorescence labeled secondary antibodies. Cells were mounted in ProLong gold with DAPI (life technologies, #P36931) and analyzed using a Zeiss Laser scanning microscope (LSM700). A B C D MV-4-11B cells treated withtheindicatedcompounds and concentrationsfor24h. A: DMSO control, B: 60 nM volasertib, C: 10 nM BI 894999, D: combination of both. Cytospinsandimmunofluorescence staining for tubulin (green), DNA (DAPI, blue) and pH3 (red). High number of apoptoticcellsalready after 24hrs

  7. Supplement Fig. 5.1: FACS analysis of peripheralblood of control mice at day 8 andday 39 Mouse 1 Mouse 2 Mouse 3 Day 8 Day 8 Day 39 Mouse 1 Mouse 2 E+04:2,39 3,38 2,80 E+07: 9,60 4,30 1 2 3 Day 39 1 2 Method: Peripheral blood was collected and red blood cell lysis was performed with BD Phram Lyse (BD Bioscience). Cells were stained with anit-human-CD45-PE antibody (Clone: 2D1; AffymetrixeBioscience) as described in the eBioscience data sheet. Flow cytometer were acquired on a FACSCalibur (BD Bioscience) and data analysis was performed with FlowJosofware (Tree Star). CD45 FCS

  8. Supplement Fig. 5.2: FACS analysis of bone marrow of mice treated with 4 mg/kg BI 894999 and 20 mg/kg volasertib at day 149 Mouse 49 Mouse 50 Mouse 51 Mouse 52 Mouse 54 Mouse 55 Mouse 56 CD45 Method: Bone marrow was collected form the femur and red blood cell lysis was performed with BD Phram Lyse (BD Bioscience). Cells were stained with anit-human-CD45-PE antibody (Clone: 2D1; AffymetrixeBioscience) as described by the eBioscience data sheet. Flow cytometer were acquired on a FACSCalibur (BD Bioscience) and data analysis was performed with FlowJosofware (Tree Star). All animals were animals were sacrificedt at day 149 FCS

  9. Supplement Fig. 6 MV-4-11B xenograft: Median bodyweightchange MV-4-11B xenograft: Single animals Radiance [p/sec/cm2/sr] Log scale vehicle Vehicle control 4 mg/kg BI 894999 2 mg/kg BI 894999 20 mg/kg volasertib 2 mg/kg BI 894999 4 mg/kg BI 894999 2 mg/kg BI 894999 + 20 mg/kg volasertib 4 mg/kg BI 894999 + 20 mg/kg volasertib 20 mg/kg volasertib 2 mg/kg BI 894999 + 20 mg/kg volasertib 4 mg/kg BI 894999 + 20 mg/kg volasertib

  10. Supplement Fig. 7 THP-1 xenograft: Median bodyweightchange THP-1 xenograft: Single animals Log scale Vehicle control 4 mg/kg BI 894999 20 mg/kg volasertib 0.5mg/kg Decitabine 4 mg/kg BI 894999 + 20 mg/kg volasertib 4 mg/kg BI 894999 + 0.5 mg/kg decitabine Volasertib 20 mg/kg BI 894999 4 mg/kg + Volasertib 20 mg/kg

  11. Supplement Fig. 8 Cell lines were cultured according to the manufacturer's instruction and authenticated by short tandem repeat (STR) analysis at BoehringerIngelheim on the dates indicated

More Related